BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37477142)

  • 1. Polo‑like kinase 1 selective inhibitor BI2536 (dihydropteridinone) disrupts centrosome homeostasis via ATM‑ERK cascade in adrenocortical carcinoma.
    Lin RC; Chao YY; Lien WC; Chang HC; Tsai SW; Wang CY
    Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37477142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
    Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
    Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
    Choi M; Kim W; Cheon MG; Lee CW; Kim JE
    Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1.
    Zou J; Zhang D; Qin G; Chen X; Wang H; Zhang D
    Cell Cycle; 2014; 13(23):3685-97. PubMed ID: 25483079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
    Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
    J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
    Kadletz L; Bigenzahn J; Thurnher D; Stanisz I; Erovic BM; Schneider S; Schmid R; Seemann R; Birner P; Heiduschka G
    Head Neck; 2016 Apr; 38 Suppl 1():E1918-25. PubMed ID: 26713885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
    Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
    Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors.
    Pereira SS; Monteiro MP; Costa MM; Ferreira J; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    J Cell Biochem; 2019 Jan; 120(1):894-906. PubMed ID: 30256438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATM is activated by mitotic stress and suppresses centrosome amplification in primary but not in tumor cells.
    Shen K; Wang Y; Brooks SC; Raz A; Wang YA
    J Cell Biochem; 2006 Dec; 99(5):1267-74. PubMed ID: 16775842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
    Pezzani R; Rubin B; Bertazza L; Redaelli M; Barollo S; Monticelli H; Baldini E; Mian C; Mucignat C; Scaroni C; Mantero F; Ulisse S; Iacobone M; Boscaro M
    Invest New Drugs; 2016 Oct; 34(5):531-40. PubMed ID: 27177645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel pathway of centrosome amplification that does not require DNA lesions.
    Tsuda M; Tanaka M; Mushiake M; Takahashi J; Tanaka K; Watase J; Fujisawa J; Miwa M
    Cancer Sci; 2012 Feb; 103(2):191-6. PubMed ID: 22085410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
    Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
    Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
    Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
    J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
    Chimento A; Sirianni R; Casaburi I; Zolea F; Rizza P; Avena P; Malivindi R; De Luca A; Campana C; Martire E; Domanico F; Fallo F; Carpinelli G; Cerquetti L; Amendola D; Stigliano A; Pezzi V
    Oncotarget; 2015 Aug; 6(22):19190-203. PubMed ID: 26131713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of centrosome amplification after DNA damage depends on p27 accumulation.
    Sugihara E; Kanai M; Saito S; Nitta T; Toyoshima H; Nakayama K; Nakayama KI; Fukasawa K; Schwab M; Saya H; Miwa M
    Cancer Res; 2006 Apr; 66(8):4020-9. PubMed ID: 16618721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over expression of DNA damage and cell cycle dependent proteins are associated with poor survival in patients with adrenocortical carcinoma.
    Subramanian C; Cohen MS
    Surgery; 2019 Jan; 165(1):202-210. PubMed ID: 30413320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
    De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.